CRBP
Corbus Pharmaceuticals Holdings, Inc. NASDAQ Listed Oct 27, 2014$10.86
Mkt Cap $136.1M
52w Low $6.25
32.2% of range
52w High $20.56
50d MA $9.52
200d MA $10.27
P/E (TTM)
-1.8x
EV/EBITDA
-1.0x
P/B
0.9x
Debt/Equity
0.0x
ROE
-53.2%
P/FCF
-1.7x
RSI (14)
—
ATR (14)
—
Beta
2.79
50d MA
$9.52
200d MA
$10.27
Avg Volume
207.8K
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
500 River Ridge Drive · Norwood, MA 02062 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | BMO | — | — | — | 10.87 | +0.1% | +0.8% | — | — | — | — | — |
| May 7, 2026 | BMO | — | — | — | 10.92 | -0.5% | -0.5% | — | — | — | — | — |
| Mar 9, 2026 | BMO | -1.78 | -1.25 | +29.8% | 9.55 | +1.7% | +5.1% | +5.1% | +9.2% | +0.4% | -1.5% | — |
| Nov 12, 2025 | BMO | -1.80 | -1.90 | -5.6% | 11.19 | +1.0% | -1.1% | -1.1% | -1.1% | +0.5% | +7.3% | — |
| Aug 5, 2025 | BMO | -1.55 | -1.44 | +7.1% | 8.90 | +1.7% | +2.4% | +2.4% | +1.1% | -5.3% | -2.6% | — |
| May 6, 2025 | BMO | -1.26 | -1.39 | -10.3% | 6.25 | +5.1% | -1.9% | -1.9% | +6.4% | +3.2% | +14.6% | — |
| Mar 11, 2025 | BMO | -1.02 | -0.78 | +23.5% | 6.88 | -0.4% | +0.4% | +0.4% | -6.7% | -1.3% | +1.2% | — |
| Nov 7, 2024 | BMO | -0.99 | -1.15 | -16.2% | 18.52 | -0.3% | +1.4% | +1.4% | +0.4% | -3.1% | -1.9% | — |
| Aug 6, 2024 | BMO | -1.16 | -0.90 | +22.4% | 52.94 | +3.0% | -8.8% | -8.8% | +1.2% | +6.9% | -1.0% | — |
| May 7, 2024 | BMO | -1.09 | -0.83 | +23.9% | 39.77 | +0.6% | +6.6% | +6.6% | +10.0% | +8.1% | +7.8% | — |
| Mar 12, 2024 | BMO | -2.36 | -1.81 | +23.3% | 44.58 | +4.0% | +5.6% | +5.6% | +1.2% | -2.0% | -6.6% | — |
| Nov 7, 2023 | BMO | -2.06 | -2.27 | -10.2% | 4.20 | +4.8% | -9.0% | -9.0% | -23.6% | -22.6% | -24.8% | — |
| Aug 8, 2023 | BMO | -3.10 | -2.05 | +33.9% | 6.44 | -2.3% | -4.5% | -4.5% | -0.9% | +4.0% | +1.7% | — |
| May 9, 2023 | BMO | -4.09 | -4.24 | -3.7% | 8.87 | +10.4% | +5.0% | +5.0% | +5.4% | +10.9% | +18.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Guggenheim | Initiates | Buy | $45 | $9.82 | $10.29 | +4.8% | +0.0% | +0.6% | +4.9% | +7.1% | +8.7% |
| Mar 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.55 | $9.71 | +1.7% | +5.1% | +9.2% | +0.4% | -1.5% | -0.4% |
| Nov 13 | RBC Capital | Maintains | Outperform → Outperform | — | $11.19 | $11.30 | +1.0% | -1.1% | -1.1% | +0.5% | +7.3% | +5.6% |
| Oct 20 | Wedbush | Maintains | Outperform → Outperform | — | $19.32 | $20.50 | +6.1% | -5.4% | +0.2% | -8.2% | -10.0% | -12.6% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.32 | $20.50 | +6.1% | -5.4% | +0.2% | -8.2% | -10.0% | -12.6% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.27 | $10.31 | +0.4% | +13.1% | +13.1% | +12.0% | +12.6% | +12.4% |
| Aug 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.90 | $9.05 | +1.7% | +2.4% | +1.1% | -5.3% | -2.6% | +0.7% |
| May 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.25 | $6.57 | +5.1% | -1.9% | +6.4% | +3.2% | +14.6% | +16.2% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.25 | $6.57 | +5.1% | -1.9% | +6.4% | +3.2% | +14.6% | +16.2% |
| May 7 | RBC Capital | Maintains | Outperform → Outperform | — | $6.25 | $6.57 | +5.1% | -1.9% | +6.4% | +3.2% | +14.6% | +16.2% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.88 | $6.85 | -0.4% | +0.4% | -6.7% | -1.3% | +1.2% | -8.0% |
| Mar 11 | Jefferies | Maintains | Buy → Buy | — | $6.79 | $7.10 | +4.6% | +1.3% | +1.8% | -5.4% | +0.0% | +2.5% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.51 | $8.70 | +2.2% | -3.5% | -8.3% | -2.7% | -3.9% | -11.0% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.15 | $10.35 | +2.0% | -3.6% | -13.5% | -11.1% | -6.6% | -16.2% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $52.94 | $54.51 | +3.0% | -8.8% | +1.2% | +6.9% | -1.0% | +0.1% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $52.94 | $54.51 | +3.0% | -8.8% | +1.2% | +6.9% | -1.0% | +0.1% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $55.03 | $55.37 | +0.6% | -3.8% | -12.2% | -2.6% | +2.8% | -4.8% |
| Jul 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $51.08 | $51.32 | +0.5% | +0.8% | +4.4% | +15.3% | +16.0% | +18.0% |
| Jun 11 | RBC Capital | Maintains | Outperform → Outperform | — | $43.87 | $43.87 | +0.0% | +14.7% | +16.8% | +20.6% | +14.2% | +0.8% |
| Jun 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $42.80 | $45.00 | +5.1% | +9.4% | +10.1% | +9.9% | +8.9% | +3.1% |
| May 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $39.77 | $39.99 | +0.6% | +6.6% | +10.0% | +8.1% | +7.8% | +8.1% |
| Mar 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $44.58 | $46.36 | +4.0% | +5.6% | +1.2% | -2.0% | -6.6% | -4.1% |
| Mar 6 | Jefferies | Upgrade | Hold → Buy | — | $34.60 | $38.95 | +12.6% | -2.9% | +16.5% | +29.9% | +10.6% | +28.8% |
| Jan 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $29.49 | $24.90 | -15.6% | -36.9% | -14.7% | -10.2% | -5.8% | -9.4% |
| Aug 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.44 | $6.29 | -2.3% | -4.5% | -0.9% | +4.0% | +1.7% | -0.5% |
| May 10 | Oppenheimer | Upgrade | Perform → Outperform | — | $8.87 | $9.79 | +10.4% | +5.0% | +5.4% | +10.9% | +18.4% | +17.7% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.66 | $2.81 | +5.6% | -5.3% | -11.3% | -19.5% | -15.4% | +15.4% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.30 | $35.40 | -2.5% | +1.7% | -0.8% | -5.8% | -7.4% | -8.7% |
| Sep 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.90 | $68.10 | +1.8% | +9.4% | +1.8% | -15.7% | -13.5% | -11.7% |
| Sep 8 | BTIG | Downgrade | Buy → Neutral | — | $277.50 | $66.90 | -75.9% | -75.9% | -73.6% | -75.5% | -79.7% | -79.1% |
| Sep 8 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $277.50 | $66.90 | -75.9% | -75.9% | -73.6% | -75.5% | -79.7% | -79.1% |
| Sep 8 | Roth Capital | Downgrade | Buy → Neutral | — | $277.50 | $66.90 | -75.9% | -75.9% | -73.6% | -75.5% | -79.7% | -79.1% |
| Jun 17 | BTIG | Maintains | Buy → Buy | — | $227.40 | $236.10 | +3.8% | +3.2% | +5.1% | +1.3% | +3.4% | +7.5% |
| Jun 4 | Nomura Instinet | Maintains | Buy → Buy | — | $209.70 | $210.60 | +0.4% | -1.4% | -1.4% | +2.3% | +0.3% | +4.6% |
| Mar 26 | Nomura | Maintains | Buy → Buy | — | $147.90 | $152.10 | +2.8% | +13.2% | +5.5% | +11.8% | +6.3% | -2.8% |
| Apr 5 | Jefferies | Maintains | Buy → Buy | — | $212.40 | $221.40 | +4.2% | +10.2% | +3.1% | +0.1% | -1.0% | -0.3% |
| Mar 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $206.10 | $220.50 | +7.0% | +8.7% | +5.7% | +11.8% | +2.6% | +5.5% |
| Dec 26 | H.C. Wainwright | Maintains | Buy → Buy | — | $157.80 | $163.50 | +3.6% | +6.7% | +12.4% | +11.8% | +11.0% | +24.5% |
| Dec 7 | RBC Capital | Maintains | Outperform → Outperform | — | $199.80 | $209.70 | +5.0% | +3.6% | +1.5% | +3.6% | +3.2% | -0.5% |
| Oct 24 | B. Riley FBR | Maintains | Buy → Buy | — | $214.20 | $225.90 | +5.5% | -3.9% | -3.9% | -5.2% | -8.5% | -7.6% |
| Sep 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $151.50 | $159.00 | +5.0% | -2.0% | -4.0% | +1.0% | +2.5% | +57.4% |
| Jan 19 | Raymond James | Maintains | Outperform → Outperform | — | $238.50 | $259.50 | +8.8% | +3.8% | +10.7% | +13.2% | +14.5% | +11.9% |
| Mar 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $270.00 | $246.00 | -8.9% | -11.7% | -8.3% | -10.6% | -10.6% | -13.9% |
| Oct 5 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $210.60 | $230.70 | +9.5% | +26.4% | +24.1% | +39.5% | +36.3% | +37.9% |
| Oct 4 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $206.10 | $210.00 | +1.9% | +2.2% | +29.1% | +26.8% | +42.5% | +39.3% |
| Mar 7 | Aegis Capital | Maintains | Buy → Buy | — | $49.50 | $51.30 | +3.6% | +10.3% | +3.0% | +4.2% | +2.4% | +6.1% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CRBP's departure of a key executive effective April 15, 2026 creates uncertainty about leadership continuity and strategy execution, potentially pressuring the stock until a successor is announced.
Apr 16
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Corby Pharmaceuticals is advancing CRB-913, a weight-loss candidate, into a pivotal Phase 2b trial with 240 patients, which could validate efficacy and support faster development in the lucrative obesity market.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Corbus gained FDA clarity on CRB-701's regulatory pathway with a potentially faster approval route via accelerated approval, reducing development risk and bringing a competitive oncology asset closer to commercialization.
Apr 7
8-K · 7.01
! Medium
Corbus Pharmaceuticals Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Corbus Pharmaceuticals disclosed fourth-quarter and full-year 2025 financial results and corporate updates, positioning itself as a clinical-stage oncology and obesity-focused biotech company advancing toward potential therapeutic breakthroughs.
Mar 9
8-K · 7.01
! Medium
Corbus Pharmaceuticals Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Corbus Pharmaceuticals updated its investor presentation materials, likely reflecting changes in business strategy, pipeline progress, or financial positioning that management wants to communicate to investors.
Feb 25
Data updated apr 25, 2026 3:03am
· Source: massive.com